Company news

Nasus Pharma Ltd. news in 2026

Nasus Pharma Ltd.'s news releases, calls and decks from 2026, newest first.

View company

Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis

September 14, 2026

Nasus Pharma Announces Transition of Chief Financial Officer

August 19, 2026

Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update

August 17, 2026

Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth

July 28, 2026

Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)

June 9, 2026

Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update

March 25, 2026

Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold

March 16, 2026

Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study

March 9, 2026

Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum

March 9, 2026

Nasus Pharma to Participate in Upcoming Investor Conferences

February 20, 2026

Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026

February 17, 2026

Nasus Pharma Announces Closing of $15.0 Million Private Placement

February 13, 2026

Nasus Pharma Announces Pricing of $15.0 Million Private Placement

February 10, 2026

Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder

January 20, 2026

Decks in 2026